>

Case Studies

Filtered by Service Areas
Filtered by Therapeutic Areas
arrow&v
arrow&v

I'm a paragraph. Click here to add your own text and edit me. It's easy.

Services Area

Therapeutic Area

I'm a paragraph. Click here to add your own text and edit me. It's easy.

Services Area

Therapeutic Area

What can portfolio management do for molecule teams?

Project teams need governance portfolio context to inform their investment proposals

Services Area

Portfolio Management (Molecule Teams)

Therapeutic Area

N/A

What can portfolio management do for early commercialization?

Commercial Heads need to develop specific disease area strategies and seek Governance approval Teams need guidance on governance-approved TA priorities (e.g., TPP hurdles; prioritized indications and/or MOAs, development plans, diagnostic strategies)

Services Area

Portfolio Management (Early Commercialization)

Therapeutic Area

N/A

What can portfolio management do for governance?

Senior committees need consistent and insightful portfolio reports to help frame investment proposals in the broader portfolio context and upcoming decisions Senior leaders need new or improved processes to enable cross-functional communication and consistent evaluations of pipeline projects

Services Area

Portfolio Management (Governance)

Therapeutic Area

N/A

Website assessment for early stage biopharmaceutical company

A small, pre-clinical biopharmaceutical company wanted to assess their current website among relevant users (Doctors and Venture Capitalists) and identify areas for improvement

Services Area

Market Research (Qualitative)

Therapeutic Area

Central Nervous System (Alzheimer's, Lysosomal Storage Disorders)

Market research for novel cell transplant procedure

A small Biotech company wanted to understand similarities and differences for their developmental cell transplantation process with current ASCT processes The company was unsure what their process would cost, and wanted to understand what current ASCT procedures cost, and what parts of that cost would carry over to their process

Services Area

Market Research (Qualitative)

Therapeutic Area

Oncology (ASCT)

Support services optimization for orphan specialty product portfolio

A mid-sized pharmaceutical client desired multi-year support to help define, implement, and market a suite of support services for their portfolio of premium-priced orphan specialty products Support services included enrollment, financial/ reimbursement, patient education, and monthly lab monitoring TA highly competitive with multiple launches expected during the project

Services Area

Market Research

Therapeutic Area

Gene Therapy & Orphan Disease (Orphan)

Demand modeling and scenario planning for a novel, mass-market agent for hypercholesterolemia

A small but highly-valued biopharma client sought to quantify the opportunity for a new hypercholesterolemia product across 6 patient segments and 3 physician specialties More specifically, they wanted to know which product attributes will drive share uptake vs. the market-leading statins and the classes in late-stage development (PCSK9i and CETPi)

Services Area

Market Research (Demand Modelling, Scenario Planning)

Therapeutic Area

Other Therapeutic Areas (Cardiovascular)

Positioning for a novel, ultra-orphan specialty drug: KOL and payer deep dive

A privately-held, development stage pharmaceutical company wanted to understand the prevalence and unmet needs of an ultra-orphan disease and how a new drug might be priced and positioned to optimize uptake More tactically, the team wanted to know how to identify these ultra-rare patients for clinical trials and commercialization

Services Area

Market Research (KOL, Payor, Benchmarking)

Therapeutic Area

Gene Therapy & Orphan Disease (Orphan)

What is the market potential for a novel formulation for treating Diabetic Foot Ulcers?

A top 50 global pharma company wanted to know how they could reach $500M US peak sales for a Phase 2/3 drug treating latent tuberculosis (LTBI) The company also sought advice on how to re-frame the large and ill-defined literature prevalence to a more realistically addressable universe of patients, as well as identifying ways to grow that market

Services Area

Market Research (Market Forecast, TPP Development)

Therapeutic Area

Other Therapeutic Areas (Diabetic Foot Ulcer)

How to forecast R&D costs and allocate resources appropriately for a rare disease company?

What is a starting point for R&D resource needs for a Buy Up? What are the drivers by activity and/or function? What is the expected R&D resource demand across the portfolio?

Services Area

Portfolio Management (Activity-Based Costing)

Therapeutic Area

Gene Therapy & Orphan Drugs (Orphan)

Process overhaul at a Top 5 pharma

After a large merger, there was a need to align R&D portfolio data systems, investment valuation methodologies, and data processes Need for a flexible data system and processes that could handle asset valuations for portfolio decision making, 1-off BD valuation scenarios, and global assumptions instead of U.S.-only

Services Area

Portfolio Management

Therapeutic Area

N/A

What is the go-to-market strategy in the U.S. for an Asia-based medical device startup company?

Go-to-market strategy in the US and Asia Investment business case for lead product, and impact on company valuation for fundraising Need for a “roadshow” presentation about the company’s U.S. value proposition

Services Area

Commercial Strategy (Go-to-market Strategy, Valuation, Investment Deck Preparation)

Therapeutic Area

Other Therapeutic Areas (Medical Devices)

Analytical model to understand IP-driven commercial risks to an oncology portfolio

What are the biggest IP-driven commercial risks to an oncology portfolio? Which risks are most sensitive to patent, exclusivity, targeted combination, formulation, & line extension assumptions?

Services Area

Commercial Strategy (Modeling, Intellectual Property)

Therapeutic Area

Oncology (Immuno-oncology)

Determine the better investment (in-house vs in-license) option for a small molecule drug

A mid-side biotech company wanted to explore adding a small molecule inhibitor to a newly discovered target in their therapeutic area They wanted to determine the cost : benefit ratio of two options Develop the small molecule inhibitor in-house In-license a small molecule inhibitor from another company

Services Area

Commercial Strategy (Valuation, Business Development)

Therapeutic Area

Central Nervous System (Parkinson's, ALS)

Develop a strategic outlook for an infectious disease (ID) area and define organizational framework

Create a disease area strategy to align global and company specific views for an ID area Define commercialization challenges and unmet need in the ID area Enhance PTS for the assets in the ID area

Services Area

Commercial Strategy (TPP Development, Disease Area Strategy)

Therapeutic Area

Other Therapeutic Areas (Infectious Disease)

Platform technology technical evaluation and deal trends

A large biopharmaceutical company wanted to evaluate 3 novel platform technologies in development based on technical merits and feasibility The client wanted to determine the degree to which they would integrate and harmonize with their current portfolio and disease areas of focus Lastly, the client wanted to understand the competitive landscape and recent deal trends for prioritized platform(s)

Services Area

Commercial Strategy (Technical Assessment)

Therapeutic Area

Other Therapeutic Areas (CAR-T, CRISPR), Gene Therapy

Strategic competitive intelligence assessments

Understand the competitive landscape for several disease areas Gain insights from the design and success/failures of competitor clinical trials Evaluate strategic importance of PK and/or PD biomarkers Prioritize competitive threats based on a review of competitor MOA, published literature, and execution

Services Area

Commercial Strategy (Competitive Insights)

Therapeutic Area

Central Nervous System (Alzheimer's, Parkinson's, ALS)

Immuno-oncology competitive intelligence

A mid-size biotech company has an immuno-oncology therapy with a new MOA in clinical trials They want to determine the current and future landscape for immuno-oncology products, especially with unique MOAs Gain insights from competitors clinical trials and launches and create a differentiation strategy

Services Area

Commercial Strategy (Competitive assessment)

Therapeutic Area

Oncology (Solid Tumor, Immuno-oncology)

Technology prioritization for stem cell (iPSC) regenerative medicine technology

A venture capital firm wanted to understand the landscape of a new stem cell platform technology for use in the regenerative medicine field They wanted to comprehend the technical advantages, stage of development, therapeutic uses, technical feasibility and intellectual property surrounding the technology.

Services Area

Commercial Strategy (Technical Assessment)

Therapeutic Area

Oncology (Stem Cell)

Landscape assessment, development opportunities, and forecasting for novel prostate cancer molecule

A privately-held, development stage pharmaceutical company wanted to understand the current and future treatment landscape of prostate cancer, opportunities for novel platform development, and forecast peak year sales across several potential indications TA has complex market dynamics, with other products gaining additional indications and targeted therapies expected to become more prominent in the market

Services Area

Commercial Strategy (Market Forecast, Competitive Assessment)

Therapeutic Area

Oncology (Solid Tumor, Prostate)

Market forecast and technology valuation for a novel immuno-oncology cell therapy

A UniveristyTechnical Transfer Office wants to analyze an internal novel cell therapy product indicated for several cancers They wanted to prioritize the indications and understand the potential market over 20 years for the product across different geographies, including US, EU, Japan and China. The client wanted to negotiate the licensing of the technology based on the market forecast and previous licensing deals

Services Area

Commercial Strategy (Valuation and Market Forecast)

Therapeutic Area

Oncology (Cell Therapy, Hematology)

Detailed global sales forecast and NPV model in Ulcerative Colitis and Crohn’s Disease

A privately-held, development stage pharmaceutical company wanted to understand the market and NPV potential of its two lead assets in Ulcerative Colitis and Crohn’s Disease to support conversations with potential investors The Company’s TPPs and evolving standard of care required a more complex approach to patient segmentation to allow different uptake assumptions across patient profiles

Services Area

Commercial Strategy (Valuation)

Therapeutic Area

Auto-immune (UC and Crohn's)

Indication prioritization for platform technology

Our client, a mid-size biotech company, has a platform technology to cross the blood brain barrier and deliver a novel therapeutic modality The client wanted to first identify indications with an unmet need that would benefit from the novel therapeutic modality The client then wanted to build a framework for prioritizing indications, and to create a commercialization strategy for each prioritized indication

Services Area

Commercial Strategy (Indication Assessment)

Therapeutic Area

Central Nervous System (Alzheimer's)

How to prioritize indications for an early stage company with a disruptive technology?

Our client is a lean, well-funded early stage company focused on advancing cutting-edge research into development The scientifically savvy senior leadership needed on-demand consultation to tackle recurring analyses and novel strategic problem solving, in order to support key corporate decisions

Services Area

Commercial Strategy (Indication Prioritization)

Therapeutic Area

Central Nervous System

Portfolio planning and management

A mid-size biotechnology company wanted to organize its proprietary therapeutic technology portfolio for 3 disease areas They wanted a framework to for portfolio management to drive growth and realize full potential of the platform technology through product and portfolio assessments Specifically, they wanted to identify opportunities, gaps and risks in the portfolio and enable selection and prioritize new programs for internal portfolio

Services Area

Commercial Strategy (Indication Prioritization)

Therapeutic Area

Gene Therapy & Orphan Disease

Company Strategy Alignment

Our client is a privately-held, clinical stage company in need of communicating a coherent corporate strategy to the equity market The executive committee retained us to poll the opinions of its members, and to design and facilitate an offsite that would result in an informed, aligned strategy for the company

Services Area

Commercial Strategy (Corporate Strategy)

Therapeutic Area

Infectious Disease

Indication evaluation and prioritization for development stage pharmaceutical client

A privately-held, development stage pharmaceutical company wanted to understand the clinical and commercial factors across a breadth of indications in order to prioritize development There were initial thoughts on several broad disease areas, but no concrete goal or therapeutic target

Services Area

Commercial Strategy (Indication Prioritization)

Therapeutic Area

Gene Therapy & Orphan Disease

How to prioritize indications for an early stage company with a disruptive technology?

Which indications are best suited as a first indication for a new technology? How do commercial, technical, and clinical considerations inform this recommendation? What makes the indication(s) compelling? What concerns should be addressed?

Services Area

Commercial Strategy (Indication Prioritization)

Therapeutic Area

Gene Therapy & Orphan Disease

On-demand, Short-term Ops Support for a Pre-IND Biotech

Our client is a seed-stage startup focused on IND filing for a novel cell therapy, which requires complex protein engineering and an extensive manufacturing supply chain The executive team requested a short-term engagement to assist the team in better understanding its timelines and creating board-ready slides to communicate the status of manufacturing activities

Services Area

Operation Strategy (CMC)

Therapeutic Area

Oncology, Other Therapeutic Areas

Assess the biosimilars market and create a medical affairs strategy to prepare for biosimilar launches

A large biopharmaceutical company wants to assess the regulatory and clinical biosimilars market to enable informed treatment decision making in the best interest of patients

Services Area

Operation Strategy (medical affairs)

Therapeutic Area

Oncology (immunoncology)

Launch messaging and positioning for a specialty product

A mid-sized pharma client wanted to evaluate quantitatively the impact of launch messaging and positioning for a orphan specialty product (messages spanned efficacy, safety, reimbursement, and enrollment) In addition, they wanted to ensure the messaging is complementary to the messaging for related products in their portfolio

Services Area

Market Research (launch messaging and positioning)

Therapeutic Area

Gene Therapy & Orphan Disease

Market research for novel oncology drug with NGS vs. IHC diagnostic strategy

A mid size biotech company has a drug targeting a rare cancer mutation and wanted to plan an (ideal) CDx test to accompany the drug launch They wanted to determine the current usage and future adoption of different molecular diagnostic platforms (single analyte, NGS and liquid biopsy) Understand the pro's and con's of each platform and determine stakeholders (payers and physicians) perceptions

Services Area

Market Research (Quantitative and Qualitative Study)

Therapeutic Area

Oncology (diagnostics, NGS, Solid Tumor)

US quantitative market assessment: novel therapy for infectious disease

A top 50 global pharma company wanted to know how they could reach $500M US peak sales for a Phase 2/3 drug treating latent tuberculosis (LTBI) The company also sought advice on how to re-frame the large and ill-defined literature prevalence to a more realistically addressable universe of patients, as well as identifying ways to grow that market

Services Area

Market Research (Quantitive & Qualitative Study, TPP testing, Market Forecast Research)

Therapeutic Area

Other Therapeutic Areas (Infectious Disease, Tuberculosis)

Analytics overhaul at a top 10 pharma

Project team investments proposed to decision-making executives did not use a consistent set of financial valuation data or tools, nor were these easily shared or aggregated into a portfolio view As a result, there was a need for a single system with shared financial assumptions and methodologies for reporting and decision making

Services Area

Portfolio Management

Therapeutic Area

N/A

Pre-clinical Stage, Cutting Edge Biotech in Need of Strategy and Analysis Leverage

Our client is a lean, well-funded early stage company focused on advancing cutting-edge research into development The scientifically savvy senior leadership needed on-demand consultation to tackle recurring analyses and novel strategic problem solving, in order to support key corporate decisions

Services Area

Commercial Strategy

Therapeutic Area

Central Nervous System

What is the product positioning strategy for two novel early stage IO candidates for global pharma company?

Which indications should the IO candidates be prioritized for? How does the product positioning affect the overall IO portfolio for the company? Go/no-go decision on mono / combotherapy

Services Area

Commercial Strategy, Portfolio Management (Disease Area Strategy)

Therapeutic Area

Oncology (Solid Tumor), Auto-immune

Quantitative market assessment of preselected diseases and selection of potential new indications

A pre-clinical client with a novel drug platform wants to identify the best market for trials and product launch. Client wanted to understand landscape and market potential for five preselected chronic diseases. Client wanted to know if any other diseases for their preselected anatomy were viable markets as well.

Services Area

Commercial Strategy (Indication Prioritization), Portfolio Management

Therapeutic Area

Gene Therapy & Orphan Disease

© 2019, First Principles Advisory Group. All Rights Reserved
SF Bay Area, Denver, Seattle, New York City, Cambridge
First Principles Advisory Group
1290 Howard Street Suite 323
Burlingame, CA 94010
(415) 669-5183
info@fpadvisory.net